Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims were To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis